Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: a 24‐week double‐blind prospective randomized controlled trial
Clémence Bertold, Eric Fontas, Tanya Singh, Nadia Gastaut, Sandra Ruitort, Sylvia Wehrlen Pugliese, Thierry Passeron- Infectious Diseases
- Dermatology
Abstract
Background
Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma. Its efficacy has never been matched before, but it is tempered by frequent adverse effects.
Objective
To assess the efficacy and tolerance of a New Trio (NT) combination with isobutylamido‐thiazolyl‐resorcinol, retinoic acid and cortosteroid compared to KT.
Methods
We conducted a 24‐week monocentric trial, randomized, double‐blind, controlled versus KT, with 40 melasma patients. NT and KT were applied for 12 weeks and associated with the same sunscreen applied for 24 weeks. The primary endpoint was the modified Melasma Area Severity Index (mMASI) at 12 weeks. Patient quality of life was investigated using MelasQoL.
Results
After 12 weeks, KT and NT groups both demonstrated a significant improvement in mMASI, respectively ‐2.84 (SE 0.69, p<0.0002), and ‐4.33 (SE 0.71, p<0.0001). The mean difference between the two groups was ‐1.49 (IC95% ‐3.52 – 0.54, p=0.14). MelasQoL improvement was ‐6.66 (SE 3.29, p=0.0515) with KT, and ‐12.57 (SE 3.29, p=0.0006) with NT.
Conclusion
The NT combination appears to be an effective treatment option for treating melasma and could be considered as a well‐tolerated alternative to KT.